Avecho Biotechnology Ltd (Avecho) continues to develop and commercialize human and animal health products using its proprietary drug delivery system, Tocopherol Phosphate Mixture (TPM). This multi-functional and multi-component delivery technology is based on vitamin E and is designed to enhance the solubility and absorption of drugs and nutrients through oral, dermal, and transdermal routes.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Avecho has been actively engaged in research and development initiatives, focusing on leveraging its proprietary Tocopherol Phosphate Mixture (TPM) technology to enhance drug delivery systems. The company's R&D efforts are primarily directed towards the development of its lead product, a cannabidiol (CBD) TPM soft-gel capsule, which is currently undergoing Phase III clinical trials for the treatment of insomnia. The trial is a pivotal, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of the CBD TPM soft-gel capsules in adults with insomnia. Avecho has expanded the trial to include additional sites and has implemented protocol amendments to increase recruitment efficiency. The company anticipates completing the interim analysis in the first half of 2026. Additionally, Avecho has received R&D tax incentives and grants from the Australian Government, which have been instrumental in supporting its ongoing clinical development expenses. In FY2025, the company incurred an expense AUD4.3 million on its research and development activities.